Novel Biologic Agents for Multiple Sclerosis and Their Impact on Managed Care
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system that is associated with progressive disability and cognitive dysfunction. Advances in our understanding of MS pathogenesis and DNA technology have led to the development of several novel biologic agents that tar...
Gespeichert in:
| Veröffentlicht in: | Formulary (Cleveland, Ohio) Ohio), 2004-11, p.15 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 15 |
| container_title | Formulary (Cleveland, Ohio) |
| container_volume | |
| creator | Chao, Schumarry H Smith, Craig H |
| description | Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system that is associated with progressive disability and cognitive dysfunction. Advances in our understanding of MS pathogenesis and DNA technology have led to the development of several novel biologic agents that target steps in the pathogenesis of the MS lesion. As these biologic agents become available, it will be critical to evaluate their efficacy, tolerability, and routes of administration relative to currently approved agents, to determine which therapies provide the greatest clinical benefit and economic value. Furthermore, the impact on coverage for infusible biologic agents has yet to be determined in light of the recent enactment of the Medicare Prescription Drug Improvement and Modernization Act of 2003. Experience with challenges encountered with utilization of biologic agents in the treatment of rheumatoid arthritis and psoriasis, and strategies developed to affect appropriate cost-effective treatment modalities may help guide the incorporation of novel biologic agents in the management of MS. [PUBLICATION ABSTRACT] Key Words: Multiple sclerosis, managed care, biologic therapy. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_229999951</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>754773141</sourcerecordid><originalsourceid>FETCH-LOGICAL-p180t-2ddaa7cce3965c7d742684fdbb8776122bc643a96c13b6925b6e5619c5c8fd913</originalsourceid><addsrcrecordid>eNotjctOwzAUBS0EEqXwDxZ7S34kN_ayRDwqNbCgSOwqx74JqUwc7ITvpwjOZmY154yshFGaCQFwfnKuJdNcvF-Sq5yPnHMAJVekeY7fGOjdEEPsB0c3PY5zpl1MtFnCPEwB6asLmGIeMrWjp_sPHBLdfk7WzTSOtLGj7dHT2ia8JhedDRlv_rkmbw_3-_qJ7V4et_Vmxyah-cyk99ZWzqEyULrKV4UEXXS-bXVVgZCydVAoa8AJ1YKRZQtYgjCudLrzRqg1uf3rTil-LZjnwzEuaTxdHqQ0vyuF-gGDuEoS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229999951</pqid></control><display><type>article</type><title>Novel Biologic Agents for Multiple Sclerosis and Their Impact on Managed Care</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Business Source Complete</source><creator>Chao, Schumarry H ; Smith, Craig H</creator><creatorcontrib>Chao, Schumarry H ; Smith, Craig H</creatorcontrib><description>Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system that is associated with progressive disability and cognitive dysfunction. Advances in our understanding of MS pathogenesis and DNA technology have led to the development of several novel biologic agents that target steps in the pathogenesis of the MS lesion. As these biologic agents become available, it will be critical to evaluate their efficacy, tolerability, and routes of administration relative to currently approved agents, to determine which therapies provide the greatest clinical benefit and economic value. Furthermore, the impact on coverage for infusible biologic agents has yet to be determined in light of the recent enactment of the Medicare Prescription Drug Improvement and Modernization Act of 2003. Experience with challenges encountered with utilization of biologic agents in the treatment of rheumatoid arthritis and psoriasis, and strategies developed to affect appropriate cost-effective treatment modalities may help guide the incorporation of novel biologic agents in the management of MS. [PUBLICATION ABSTRACT] Key Words: Multiple sclerosis, managed care, biologic therapy.</description><identifier>ISSN: 1082-801X</identifier><identifier>EISSN: 1938-1166</identifier><language>eng</language><publisher>North Olmsted: MultiMedia Healthcare Inc</publisher><subject>Antigens ; Blood-brain barrier ; Cell adhesion & migration ; Clinical trials ; Disease ; Disease management ; Drug therapy ; FDA approval ; Immunotherapy ; Inflammatory diseases ; Leukocytes ; Lymphocytes ; Magnetic resonance imaging ; Medicare Prescription Drug Improvement & Modernization Act 2003-US ; Monoclonal antibodies ; Multiple sclerosis ; Nervous system ; Pathogenesis ; Pathology ; Prescription drugs ; Psoriasis ; Rheumatoid arthritis</subject><ispartof>Formulary (Cleveland, Ohio), 2004-11, p.15</ispartof><rights>Copyright Advanstar Communications, Inc. Nov 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Chao, Schumarry H</creatorcontrib><creatorcontrib>Smith, Craig H</creatorcontrib><title>Novel Biologic Agents for Multiple Sclerosis and Their Impact on Managed Care</title><title>Formulary (Cleveland, Ohio)</title><description>Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system that is associated with progressive disability and cognitive dysfunction. Advances in our understanding of MS pathogenesis and DNA technology have led to the development of several novel biologic agents that target steps in the pathogenesis of the MS lesion. As these biologic agents become available, it will be critical to evaluate their efficacy, tolerability, and routes of administration relative to currently approved agents, to determine which therapies provide the greatest clinical benefit and economic value. Furthermore, the impact on coverage for infusible biologic agents has yet to be determined in light of the recent enactment of the Medicare Prescription Drug Improvement and Modernization Act of 2003. Experience with challenges encountered with utilization of biologic agents in the treatment of rheumatoid arthritis and psoriasis, and strategies developed to affect appropriate cost-effective treatment modalities may help guide the incorporation of novel biologic agents in the management of MS. [PUBLICATION ABSTRACT] Key Words: Multiple sclerosis, managed care, biologic therapy.</description><subject>Antigens</subject><subject>Blood-brain barrier</subject><subject>Cell adhesion & migration</subject><subject>Clinical trials</subject><subject>Disease</subject><subject>Disease management</subject><subject>Drug therapy</subject><subject>FDA approval</subject><subject>Immunotherapy</subject><subject>Inflammatory diseases</subject><subject>Leukocytes</subject><subject>Lymphocytes</subject><subject>Magnetic resonance imaging</subject><subject>Medicare Prescription Drug Improvement & Modernization Act 2003-US</subject><subject>Monoclonal antibodies</subject><subject>Multiple sclerosis</subject><subject>Nervous system</subject><subject>Pathogenesis</subject><subject>Pathology</subject><subject>Prescription drugs</subject><subject>Psoriasis</subject><subject>Rheumatoid arthritis</subject><issn>1082-801X</issn><issn>1938-1166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNotjctOwzAUBS0EEqXwDxZ7S34kN_ayRDwqNbCgSOwqx74JqUwc7ITvpwjOZmY154yshFGaCQFwfnKuJdNcvF-Sq5yPnHMAJVekeY7fGOjdEEPsB0c3PY5zpl1MtFnCPEwB6asLmGIeMrWjp_sPHBLdfk7WzTSOtLGj7dHT2ia8JhedDRlv_rkmbw_3-_qJ7V4et_Vmxyah-cyk99ZWzqEyULrKV4UEXXS-bXVVgZCydVAoa8AJ1YKRZQtYgjCudLrzRqg1uf3rTil-LZjnwzEuaTxdHqQ0vyuF-gGDuEoS</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>Chao, Schumarry H</creator><creator>Smith, Craig H</creator><general>MultiMedia Healthcare Inc</general><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7X7</scope><scope>7XB</scope><scope>883</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>L.-</scope><scope>M0F</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYYUZ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20041101</creationdate><title>Novel Biologic Agents for Multiple Sclerosis and Their Impact on Managed Care</title><author>Chao, Schumarry H ; Smith, Craig H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p180t-2ddaa7cce3965c7d742684fdbb8776122bc643a96c13b6925b6e5619c5c8fd913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antigens</topic><topic>Blood-brain barrier</topic><topic>Cell adhesion & migration</topic><topic>Clinical trials</topic><topic>Disease</topic><topic>Disease management</topic><topic>Drug therapy</topic><topic>FDA approval</topic><topic>Immunotherapy</topic><topic>Inflammatory diseases</topic><topic>Leukocytes</topic><topic>Lymphocytes</topic><topic>Magnetic resonance imaging</topic><topic>Medicare Prescription Drug Improvement & Modernization Act 2003-US</topic><topic>Monoclonal antibodies</topic><topic>Multiple sclerosis</topic><topic>Nervous system</topic><topic>Pathogenesis</topic><topic>Pathology</topic><topic>Prescription drugs</topic><topic>Psoriasis</topic><topic>Rheumatoid arthritis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chao, Schumarry H</creatorcontrib><creatorcontrib>Smith, Craig H</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Trade & Industry (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Trade & Industry</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Research Library China</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ABI/INFORM Collection China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Formulary (Cleveland, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chao, Schumarry H</au><au>Smith, Craig H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel Biologic Agents for Multiple Sclerosis and Their Impact on Managed Care</atitle><jtitle>Formulary (Cleveland, Ohio)</jtitle><date>2004-11-01</date><risdate>2004</risdate><spage>15</spage><pages>15-</pages><issn>1082-801X</issn><eissn>1938-1166</eissn><abstract>Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system that is associated with progressive disability and cognitive dysfunction. Advances in our understanding of MS pathogenesis and DNA technology have led to the development of several novel biologic agents that target steps in the pathogenesis of the MS lesion. As these biologic agents become available, it will be critical to evaluate their efficacy, tolerability, and routes of administration relative to currently approved agents, to determine which therapies provide the greatest clinical benefit and economic value. Furthermore, the impact on coverage for infusible biologic agents has yet to be determined in light of the recent enactment of the Medicare Prescription Drug Improvement and Modernization Act of 2003. Experience with challenges encountered with utilization of biologic agents in the treatment of rheumatoid arthritis and psoriasis, and strategies developed to affect appropriate cost-effective treatment modalities may help guide the incorporation of novel biologic agents in the management of MS. [PUBLICATION ABSTRACT] Key Words: Multiple sclerosis, managed care, biologic therapy.</abstract><cop>North Olmsted</cop><pub>MultiMedia Healthcare Inc</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1082-801X |
| ispartof | Formulary (Cleveland, Ohio), 2004-11, p.15 |
| issn | 1082-801X 1938-1166 |
| language | eng |
| recordid | cdi_proquest_journals_229999951 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Business Source Complete |
| subjects | Antigens Blood-brain barrier Cell adhesion & migration Clinical trials Disease Disease management Drug therapy FDA approval Immunotherapy Inflammatory diseases Leukocytes Lymphocytes Magnetic resonance imaging Medicare Prescription Drug Improvement & Modernization Act 2003-US Monoclonal antibodies Multiple sclerosis Nervous system Pathogenesis Pathology Prescription drugs Psoriasis Rheumatoid arthritis |
| title | Novel Biologic Agents for Multiple Sclerosis and Their Impact on Managed Care |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T00%3A56%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20Biologic%20Agents%20for%20Multiple%20Sclerosis%20and%20Their%20Impact%20on%20Managed%20Care&rft.jtitle=Formulary%20(Cleveland,%20Ohio)&rft.au=Chao,%20Schumarry%20H&rft.date=2004-11-01&rft.spage=15&rft.pages=15-&rft.issn=1082-801X&rft.eissn=1938-1166&rft_id=info:doi/&rft_dat=%3Cproquest%3E754773141%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229999951&rft_id=info:pmid/&rfr_iscdi=true |